SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC

NCT07198165 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

104

Enrollment

OTHER

Sponsor class

Conditions

Rectal Cancer
Rectal Adenocarcinoma
Rectal Cancer, Radiotherapy
Rectal Cancer Patients
Immunotherapy
Total Neoadjuvant Therapy
Total Neoadjuvant Treatment
Targeted Therapy
Chemoradiotherapy

Interventions

DRUG: PD-1 inhibitor based immunotherapy

Sponsor

Ruijin Hospital